Table 3

The 30-day and 1-year adverse events in both groups

EUS-GBD
n=39
PT-GBD
n=40
P value
30-day adverse events (%)5 (12.8)19 (47.5)0.010
Tube dislodgement015 (0/3/12/0/0)
Blocked stent2 (0/1/1/0/0)0
Perforation1 (0/0/1/0/0)0
Multiorgan failure03 (0/0/0/0/3)
Pericholecystic collection01 (0/0/1/0/0)
Acute myocardial infarction01 (0/1/0/0/0)
Atrial fibrillation1 (0/1/0/0/0)1 (0/1/0/0/0)
Pneumonia3 (0/1/0/0/2)1 (0/1/0/0/0)
Bleeding01 (0/1/0/0/0)
Decompensated liver cirrhosis01 (0/0/0/0/1)
Urinary tract infection01 (0/2/0/0/0)
1-year adverse events (%)10 (25.6)31 (77.5)<0.001
30-day adverse events*519
Recurrent acute cholecystitis1 (0/0/1/0/0)8 (0/5/3/0/0)
Tube dislodgement018 (4/5/9/0/0)
Blocked stent / tube1 (0/0/1/0/0)2 (0/2/0/0/0)
Common bile duct stones requiring ERCP3 (0/0/3/0/0)1 (0/0/1/0/0)
  • *The occurrence of adverse event is based on per patient analysis, and some patients may have suffered from more than one adverse events. The severity of each adverse event is shown as Clavien-Dindo class (1/2/3/4/5).

  • GBD, gallbladder drainage; PT, percutaneous cholecystostomy.